Efficacy and Safety Profile of Cisatracurium Besylate for IAH
Status:
Not yet recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This study is a randomized, double-blinded, controlled design. In this study, Cisatracurium
Besylate was selected for treatment in Intra-abdominal hypertension or abdominal compartment
syndrome,accompanied with evaluating the effects on the duration of organ failure,length of
hospital stay and mortality.To clarify the effect of Cisatracurium Besylate on IAH/ACS is of
great significance to the clinical applications.